PEOPLE

Paul L. Berns (left) has been appointed Allos Therapeutics’ NitroMed (Lexington, MA, USA) has (Westminster, CO, USA) president, CEO and member of the board announced that Argeris (Jerry) Karabelas, of directors. He brings close to 15 years of currently chairman of the board of directors, experience to Allos, holding senior management positions at Abbott has been appointed interim CEO, succeed- Laboratories, BASF Pharmaceuticals and Bristol-Myers Squibb. Mr. ing Michael Loberg, who resigned from his Berns was most recently president, CEO and a member of the board position as president, CEO and director of of directors of Bone Care International. With Mr. Berns’ appointment, NitroMed. In addition, Kenneth Bate, formerly Michael E. Hart has resigned his positions as president, CEO and CFO of Millennium Pharmaceuticals, has been CFO, and David C. Clark, the company’s controller and treasurer, has named chief operating officer and CFO, follow- been appointed to serve as interim CFO until a permanent replacement is found. ing the departure of Lawrence Bloch as CFO and chief business officer.

Morphotek (Exton, PA, USA) has announced Privately held NascaCell IP (Munich) has was most recently head of clinical operations the appointment of Robert Radie as chief announced the appointment of cofounder at Vical. business officer and the promotion of Luigi

http://www.nature.com/naturebiotechnology Michael Blind to the position of CEO. Dr. Grasso to senior vice president of R&D. Mr. Blind was previously responsible for research VLST Corp. (Seattle, WA, USA) has announced Radie was most recently senior vice president and development activities at NascaCell. the appointment of Julie M. Eastland as CFO. of strategic projects and planning at Vicuron She joins the company from Dendreon, where Pharmaceuticals, and played an integral role in Thomas A. Bologna has been appointed presi- she was most recently vice president of strategic the company’s recent acquisition by . Dr. dent, CEO and a director of Orchid Cellmark planning. Grasso, a cofounder, has served as Morphotek’s (Princeton, NJ, USA), succeeding Paul Kelly. vice president of research since its inception. Mr. Bologna was most recently president and PDL BioPharma (Fremont, CA, USA) has CEO of Quorex Pharmaceuticals, and previ- named Andrew Guggenhime senior vice pres- Inotek (Beverly, MA, USA) has named Emma ously chairman, president and CEO of Ostex ident and CFO. He joins the company from Reeve as vice president and CFO. Ms. Reeve International. Neoforma, where he served as vice president of previously served as vice president and CFO for Nature Publishing Group Group Nature Publishing

6 corporate development before being promoted Aton Pharma until its acquisition by Merck. She Gary W. Coy has been appointed CFO of to the post of CFO in October 2000. Before then joined the Merck Research Laboratories’ 200

© Amarillo Biosciences (Amarillo, TX, USA) He joining Neoforma, Mr. Guggenhime was a vice Boston team as site head of research opera- brings over 30 years of management experience, president in the healthcare investment banking tions. most recently serving as a financial consultant group of Merrill Lynch. to the biomedical and real estate industries. The Medicines Company (Parsippany, NJ, Previously, Mr. Coy was chairman and presi- ZymoGenetics (Seattle, WA, USA) has elected USA) has named Glenn Sblendorio executive dent of Lighthouse Properties. Judith A. Hemberger to its board of directors. vice president and CFO. Mr. Sblendorio, who Dr. Hemberger recently retired from Pharmion, was involved in the original startup planning Ocera Therapeutics (San Diego, CA, USA) where she was a founder, former executive vice and served a senior vice president of business has announced the appointment of Joe president and COO, and a director since its development, returns to the company from Davie to its board of directors. Dr. Davie was inception in 2000. She also previously served as Eyetech Pharmaceuticals, where he was execu- formerly senior vice president of ’s senior vice president of business development tive vice president and CFO until Eyetech was research department, and also served as at AVAX Technologies. Dr. Hemberger currently acquired by OSI Pharmaceuticals in November senior vice president, science and technol- serves on the board of directors of Myogen, 2005. He replaces Steve Koehler, who resigned ogy at G.D. Searle. He has served on the , PRA International and Renovis. to take a position with a large pharmaceutical board of directors of Auxeris Therapeutics, company. Beyond Genomics, Curis, Inflazyme Doug Janzen has been promoted to president Pharmaceuticals, Keel Pharmaceuticals, and chief business officer of Cardiome Pharma Thomas Williams has been named CSO and Metaphore Pharmaceuticals, Neogenesis, (Vancouver, BC, Canada). Mr. Janzen joined vice president of R&D of Exagen Diagnostics Stratatech and Targeted Genetics. Ocera Cardiome in January 2003, serving as CFO. (Albuquerque, NM, USA). Dr. Williams previ- also named Karen Church as vice president Before joining the company, he was manag- ously served as the company’s special advisor of regulatory affairs and Caroline LaPlaca ing director, health sciences and partner at for molecular pathology. Additionally, he was as senior director of clinical operations. Dr. Sprott Securities, a Toronto-based investment vice chairman, department of pathology, at the Church has more than 30 years of regulatory bank. Bob Rieder will continue in his role as University of New Mexico School of Medicine affairs experience in the biopharmaceutical Cardiome’s CEO, and has been appointed vice- and director of the Genetics and Cytometry industry, most recently at Pfizer. Ms. LaPlaca chairman of the board of directors. Division at TriCore Reference Laboratories.

472 VOLUME 24 NUMBER 4 APRIL 2006 NATURE BIOTECHNOLOGY